Advertisement
Advertisement
August 28, 2026
Abbott’s 76-mm Esprit BTK System for CLTI Approved in Europe
KEY TAKEAWAYS
- Abbott received CE Mark approval for the 76-mm Esprit BTK system for the treatment of chronic limb-threatening ischemia.
- It is intended for the treatment of longer BTK lesions with fewer devices.
- The 76-mm Esprit BTK system received FDA approval in July 2026.
August 28, 2026—Abbott announced it has received CE Mark approval for its longer-length (76-mm) Esprit below-the-knee (BTK) system for the treatment of chronic limb-threatening ischemia (CLTI). In July 2026, Abbott announced FDA approval of the new 76-mm length.
According to the company, the longer-length Esprit addresses the real-world clinical need because most BTK lesions in CLTI patients exceed 100 mm. Existing lengths can require multiple scaffolds, increasing procedural time and complexity. The 76-mm length is intended to allow the treatment of longer lesions with fewer devices, noted Abbott.
The 76-mm device builds on Abbott’s Esprit BTK platform with an over-the-wire design. The dissolving resorbable scaffold with robust long-term clinical evidence, stated the company.
Advertisement
Advertisement
